[Jomar]

I did a quick search and didn't find any mention of such a thing..

But as PDers age and perhaps memory and finger dexterity lessen, a patch sure might be nice.. No forgetting, or dropping /losing pills.
Especially for those not in a care center or assisted living where meds are dispensed on a schedule.

Just wondering if any of you have seen info about something like it?

[badboy99]

I have not.

[soccertese]

there is an agonist patch NEUPRO that's been out a few years but no l-dopa patch. i think the highest dose of NEUPRO is 12-18mg for one day vs a minimum dose of L-DOPA of 300mg going up to over 1000mg so that's a lot of amino acid to pass thru the skin. there is a pump in phase 3 testing that pumps L-DOPA thru the skin like an insulin pump. DUODOPA pump is on the market but has to have a tube surgically implanted thru the stomach. in both cases, the l-dopa is very expensive, i've read over $60,000 per year for the gel.
there is also an apomorphine subcutaneous pump.

The primary technical challenge in developing a le-
vodopa transdermal patch is overcoming the poor solu-
bility and stability of levodopa

https://www.michaeljfox.org/foundati...p?grant_id=225

[Tupelo3]

Originally Posted by Jo*mar

I did a quick search and didn't find any mention of such a thing..

But as PDers age and perhaps memory and finger dexterity lessen, a patch sure might be nice.. No forgetting, or dropping /losing pills.
Especially for those not in a care center or assisted living where meds are dispensed on a schedule.

Just wondering if any of you have seen info about something like it?

There are three products currently in clinical trials that would probably interest you.

First is Acorda's CVT-301, which is a self-administered, inhaled levodopa therapy. The drug is now about half-way though several phase 3 studies with a possible NDA being filed late this year or early next year (more probable). The early results, and the phase 2 results, were all very good. It is very quick acting and has shown minimal side effects. However, at this time, it is only being tested as a "rescue-drug" for serious off periods and not for general use. I've seen the inhaler and found it a little clumsy, but still something that could be used by most patients without assistance.

Second is Cynapsus Therapeutic's APL-130277, is an which is an easy-to-administer, sublingual thin film formulation of apomorphine. When patients are OFF or begin to experience the onset of an OFF episode, they simply peel open the packaging, remove the thin film and place it under their tongue. The thin film dissolves over the course of a few minutes, allowing the apomorphine to enter into the bloodstream quickly. Cynapasus has just begun phase 3 trials and there are multiple centers across the US which will begin recruitment shortly. As with CVT, the early results have been very positive.

Third, and most closely to what you were asking about, would ne NeuroDerm's ND0612L and ND0612H. ND0612L is administered subcutaneously through a convenient, small belt-worn pump similar to the administration devices used to deliver insulin to diabetic patients. A second generation product, using a patch pump to deliver LD/CD, is under development. NeuroDerm has just begun the recruitment for a phase 2 efficacy trial.

I would highly anticipate that CVT and APL will both have successful phase 3 trials and receive FDA approval. I would anticipate they would be available by 2018, if not sooner.